Join
Live feed
·
INSIDERFilingvia Quantisnow
Cognition Therapeutics Inc. logo

Chief Financial Officer Doyle John Brendan was granted 295,000 shares, increasing direct ownership by 244% to 416,125 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
CGTX· Cognition Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CGTX (Cognition Therapeutics Inc.) and more on Quantisnow.